Gene therapy: the first decade

被引:266
作者
Mountain, A [1 ]
机构
[1] Univ Keele, Keele ST5 5SP, Staffs, England
关键词
D O I
10.1016/S0167-7799(99)01416-X
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Gene therapy promises to revolutionize medicine by treating the causes of disease rather than the symptoms. We are nearing the end of the first decade of gene therapy, and this article summarizes the approaches taken, results achieved, lessons learned and important recent developments. The early results on the clinical efficacy of gene therapies were disappointing, largely because the available gene-transfer vectors proved to be inadequate. Recently, however, clinical benefit has been clearly demonstrated and great progress made in selecting and improving vectors. There is now every prospect that the second decade will see gene therapy live up to its enormous potential.
引用
收藏
页码:119 / 128
页数:10
相关论文
共 91 条
[1]   The plasmid replicon of EBV consists of multiple cis-acting elements that facilitate DNA synthesis by the cell and a viral maintenance element [J].
Aiyar, A ;
Tyree, C ;
Sugden, B .
EMBO JOURNAL, 1998, 17 (21) :6394-6403
[2]   Towards gene therapy for cystic fibrosis: a clinical progress report [J].
Alton, EWFW ;
Geddes, DM ;
Gill, DR ;
Higgins, CF ;
Hyde, SC ;
Innes, JA ;
Porteous, DJ .
GENE THERAPY, 1998, 5 (03) :291-292
[3]   NONINVASIVE LIPOSOME-MEDIATED GENE DELIVERY CAN CORRECT THE ION-TRANSPORT DEFECT IN CYSTIC-FIBROSIS MUTANT MICE [J].
ALTON, EWFW ;
MIDDLETON, PG ;
CAPLEN, NJ ;
SMITH, SN ;
STEEL, DM ;
MUNKONGE, FM ;
JEFFERY, PK ;
GEDDES, DM ;
HART, SL ;
WILLIAMSON, R ;
FASOLD, KI ;
MILLER, AD ;
DICKINSON, P ;
STEVENSON, BJ ;
MCLACHLAN, G ;
DORIN, JR ;
PORTEOUS, DJ .
NATURE GENETICS, 1993, 5 (02) :135-142
[4]  
*AM SOC GEN THER, 1999, AM SOC GEN THER 2 AN
[5]   Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted [J].
Amalfitano, A ;
Hauser, MA ;
Hu, HM ;
Serra, D ;
Begy, CR ;
Chamberlain, JS .
JOURNAL OF VIROLOGY, 1998, 72 (02) :926-933
[6]  
Balague C, 1997, J VIROL, V71, P3299
[7]   Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab′γ)2 antibody [J].
Bartlett, JS ;
Kleinschmidt, J ;
Boucher, RC ;
Samulski, RJ .
NATURE BIOTECHNOLOGY, 1999, 17 (02) :181-186
[8]   Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia [J].
Baumgartner, I ;
Pieczek, A ;
Manor, O ;
Blair, R ;
Kearney, M ;
Walsh, K ;
Isner, JM .
CIRCULATION, 1998, 97 (12) :1114-1123
[9]   Poly(lactic-glycolic) acid copolymer encapsulation of recombinant adenovirus reduces immunogenicity in vivo [J].
Beer, SJ ;
Matthews, CB ;
Stein, CS ;
Ross, BD ;
Hilfinger, JM ;
Davidson, BL .
GENE THERAPY, 1998, 5 (06) :740-746
[10]   Efficient, repeated adenovirus-mediated gene transfer in mice lacking both tumor necrosis factor alpha and lymphotoxin α [J].
Benihoud, K ;
Saggio, I ;
Opolon, P ;
Salone, B ;
Amiot, F ;
Connault, E ;
Chianale, C ;
Dautry, F ;
Yeh, P ;
Perricaudet, M .
JOURNAL OF VIROLOGY, 1998, 72 (12) :9514-9525